BRPI0610267B8 - métodos de detecção de um estado doentio ou de uma suscetibilidade à doença em um indivíduo mamífero, e, uso do método - Google Patents

métodos de detecção de um estado doentio ou de uma suscetibilidade à doença em um indivíduo mamífero, e, uso do método

Info

Publication number
BRPI0610267B8
BRPI0610267B8 BRPI0610267A BRPI0610267A BRPI0610267B8 BR PI0610267 B8 BRPI0610267 B8 BR PI0610267B8 BR PI0610267 A BRPI0610267 A BR PI0610267A BR PI0610267 A BRPI0610267 A BR PI0610267A BR PI0610267 B8 BRPI0610267 B8 BR PI0610267B8
Authority
BR
Brazil
Prior art keywords
disease
antigen
susceptibility
detecting
antibody
Prior art date
Application number
BRPI0610267A
Other languages
English (en)
Inventor
Murray Andrea
Chapman Caroline
Forsyth Russell Robertson John
Barnes Tony
Original Assignee
Oncimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0510943A external-priority patent/GB2426581A/en
Application filed by Oncimmune Ltd filed Critical Oncimmune Ltd
Publication of BRPI0610267A2 publication Critical patent/BRPI0610267A2/pt
Publication of BRPI0610267B1 publication Critical patent/BRPI0610267B1/pt
Publication of BRPI0610267B8 publication Critical patent/BRPI0610267B8/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/104—Lupus erythematosus [SLE]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

a invenção refere-se a um método de detecção de um estado doentio ou de uma suscetibilidade à doença em um indivíduo mamífero que compreende detectar um anticorpo em uma amostra de teste compreendendo um fluido corporal de citado indivíduo mamífero no qual o citado anticorpo é um marcador biológico de um estado doentio ou de uma suscetibilidade à doença, o método compreendendo: (a) contactar a citada amostra de teste com uma pluralidade de quantidades diferentes de um antígeno específico para o citado anticorpo, (b) detectar a quantidade de ligação específica entre o citado anticorpo e o citado antígeno, (c) plotar ou calcular uma curva da quantidade de citada ligação específica versus a quantidade de antígeno para cada quantidade de antigeno usada em etapa (a) e (d) determinar a presença ou ausência de citado estado doentio ou de citada suscetibilidade à doença baseado na quantidade de ligação específica entre o citado anticorpo e o citado antígeno em cada diferente concentração de antígeno usada.
BRPI0610267A 2005-05-27 2006-05-26 métodos de detecção de um estado doentio ou de uma suscetibilidade à doença em um indivíduo mamífero, e, uso do método BRPI0610267B8 (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US68542205P 2005-05-27 2005-05-27
GB0510943A GB2426581A (en) 2005-05-27 2005-05-27 Immunoassay methods
US60/685422 2005-05-27
US60/685,422 2005-05-27
GB0510943.4 2005-05-27
PCT/GB2006/001944 WO2006126008A2 (en) 2005-05-27 2006-05-26 Improved immunoassay methods

Publications (3)

Publication Number Publication Date
BRPI0610267A2 BRPI0610267A2 (pt) 2010-06-08
BRPI0610267B1 BRPI0610267B1 (pt) 2018-01-30
BRPI0610267B8 true BRPI0610267B8 (pt) 2021-07-27

Family

ID=41460065

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0610267A BRPI0610267B8 (pt) 2005-05-27 2006-05-26 métodos de detecção de um estado doentio ou de uma suscetibilidade à doença em um indivíduo mamífero, e, uso do método

Country Status (9)

Country Link
US (2) US9714938B2 (pt)
BR (1) BRPI0610267B8 (pt)
CY (2) CY1109461T1 (pt)
IL (3) IL187481A (pt)
NO (2) NO341484B1 (pt)
NZ (1) NZ563466A (pt)
PT (1) PT1889059E (pt)
RU (2) RU2636532C2 (pt)
SI (1) SI1889059T1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2894538A1 (en) * 2013-01-31 2014-08-07 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Ari Autoantibody signature for the early detection of ovarian cancer
RU2702011C1 (ru) * 2018-11-26 2019-10-03 Владимир Леонидович Пастушенков Способ диагностики инфекционных, аллергических, аутоиммунных и онкологических заболеваний
GB2605702A (en) * 2019-09-05 2022-10-12 Avail Bio Inc Methods, compositions, and systems for profiling or predicting an immune response
WO2022192402A1 (en) * 2021-03-10 2022-09-15 Avail Bio, Inc. Methods, compositions, and systems for b-cell isolation sequencing

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4241044A (en) 1978-12-28 1980-12-23 Abbott Laboratories Method of diagnosing cancer by detecting elevated anti-T antibody activity
NZ211453A (en) 1984-03-22 1989-01-06 Biotechnology Research Enterpr Aryl azides, their preparation and use in the detection, localisation and isolation of polynucleotides
EP0236606B1 (en) 1986-03-10 1992-06-24 Imre Corporation Immune complex assay
WO1989001153A1 (en) 1987-07-24 1989-02-09 Xoma Corporation Methods for breast cancer detection
US4937185A (en) 1987-07-31 1990-06-26 The Ohio State University Research Foundation Detection of circulating antibodies to a cancer marker protein
US7282345B1 (en) 1989-08-04 2007-10-16 Schering Ag C-erbB-2 external domain: GP75
US5110911A (en) 1989-11-02 1992-05-05 Biomira, Inc. Human tumor-associated thomsen-friedenreich antigen
US5157020A (en) 1990-05-24 1992-10-20 Research Corporation Tech., Inc. Synthetic senescent cell antigen
DK9091D0 (da) 1991-01-18 1991-01-18 Novo Nordisk As Fremgangsmaade til fremstilling af antistoffer
DE4120412C1 (pt) 1991-06-20 1993-01-07 Henning Berlin Gmbh Chemie- Und Pharmawerk, 1000 Berlin, De
US6322989B1 (en) 1991-11-25 2001-11-27 Yoreh Biotechnologies, Ltd. Whole blood/mitogen assay for the early detection of a subject with ovarian or breast cancer and kit
US6280962B1 (en) 1991-11-25 2001-08-28 Yoreh Biotechnologies Ltd. Whole blood/mitogen assay for the early detection of a subject with cancer and kit
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
JPH07505719A (ja) 1992-04-14 1995-06-22 デューク・ユニバーシティー ｐ５３及びＨＳＰ７０のコンプレックスを含む腫瘍の検出方法
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US5763164A (en) 1993-04-16 1998-06-09 Northwestern University Immunogenic cancer proteins and peptides and methods of use
US5747268A (en) 1993-04-22 1998-05-05 Dade International Inc. Tumor marker control
US5744144A (en) 1993-07-30 1998-04-28 University Of Pittsburgh University Patent Committee Policy And Procedures Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof
US5721105A (en) 1994-02-20 1998-02-24 B.R.A.H.M.S. Diagnostica Gmbh Method for the immunological determination of proteins and kit for carrying out the method
JPH07294530A (ja) 1994-04-20 1995-11-10 Nippon Igaku Rinshiyou Kensa Kenkyusho:Kk 病原体に対する体液中の抗体検出法
CA2148971A1 (en) 1994-05-26 1995-11-27 Izak Bahar Calibrator matrix
ES2150573T3 (es) 1994-06-24 2000-12-01 Vladimir P Torchilin Composicion que contiene autoanticuerpos para la terapia y profilaxis tumorales.
IL110464A0 (en) 1994-07-26 1994-10-21 Univ Ramot Novel proteins for the diagnosis, imaging, and therapy of human cancer
US5561049A (en) 1994-09-21 1996-10-01 Behringwerke Ag Method for detecting antibodies
US5876728A (en) 1995-02-15 1999-03-02 Howard David Kass Natural composition extracted from plants used in the treatment of cancer
AUPN568095A0 (en) 1995-09-27 1995-10-26 Austin Research Institute, The Anti-Galalpha(1,3)Gal antibody binding peptides
GB9521544D0 (en) 1995-10-20 1995-12-20 Univ Dundee Activation of P53 protein and therapeutic applications thereof
JPH09189702A (ja) 1996-01-09 1997-07-22 Hitachi Chem Co Ltd 抗ムチン抗体の測定法、癌の測定法及び癌診断薬
AU3889997A (en) 1996-08-16 1998-03-06 Johns Hopkins University School Of Medicine, The Melanoma cell lines expressing shared immunodominant melanoma antigens nd methods of using same
EP1019727A1 (en) 1997-06-03 2000-07-19 Amdl, Inc Immunoassay for the detection of cancer
DE19805815C1 (de) 1998-02-13 1999-11-11 Ansgar W Lohse Diagnostikum zum Erkennen der autoimmunen Hepatitis
JP4083855B2 (ja) 1998-02-16 2008-04-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 肺癌予後検査方法
GB9810040D0 (en) 1998-05-11 1998-07-08 Univ Nottingham Blood borne tumour markers
AUPP349098A0 (en) 1998-05-13 1998-06-04 South Eastern Sydney Area Health Service A method of monitoring pancreatic tissue viability
ATE447713T1 (de) 1998-11-05 2009-11-15 Univ Michigan S100-proteine und -autoantikörper als serummarker für krebs
US6387639B1 (en) 1998-11-10 2002-05-14 Sloan-Kettering Institute For Cancer Research Ma family polypeptides and anti-Ma antibodies
GB9827228D0 (en) 1998-12-10 1999-02-03 Univ Nottingham Cancer detection method and reagents
US7807810B2 (en) 1999-04-08 2010-10-05 The Ohio State University Research Foundation Nucleic acids encoding the major outer membrane protein of the causative agent of human granulocytic ehrlichiosis and peptides encoded thereby
RU2181893C2 (ru) * 1999-05-25 2002-04-27 Государственный научный центр вирусологии и биотехнологии "Вектор" Способ получения референс-панели для контроля качества тест-систем и вакцин против гепатита в
US6645465B2 (en) 1999-08-06 2003-11-11 Michigan, University Of The Regents Annexin proteins and autoantibodies as serum markers for cancer
US20020064801A1 (en) 1999-12-01 2002-05-30 Ryan Jeffrey R. Novel and practical serological assay for the clinical diagnosis of leishmaniasis
US6667160B2 (en) 2000-03-15 2003-12-23 Kenneth D. Fine Method for diagnosing immunologic food sensitivity
US20030232399A1 (en) 2000-06-14 2003-12-18 Robertson John Forsyth Russell Cancer detection methods and reagents
US20030138860A1 (en) 2000-06-14 2003-07-24 Robertson John Forsyth Russell Cancer detection methods and reagents
EP1354206A2 (en) 2000-12-13 2003-10-22 Bio-Rad Laboratories, Inc. Standard diluent for multiplex assays
AU2001271554B2 (en) 2001-06-21 2009-03-12 New York University Mycobacterial proteins as early antigens for serodiagnosis and vaccines
US20030049692A1 (en) 2002-09-16 2003-03-13 Norman Latov Detection of anti-glycolipid antibodies by latex agglutination assay
GB2395270B (en) 2002-11-14 2006-08-16 Univ Nottingham Tumour marker proteins and uses thereof
JP2005352771A (ja) 2004-06-10 2005-12-22 Hitachi Software Eng Co Ltd 発現プロファイルによるパターン認識システム
US20060141547A1 (en) 2004-11-16 2006-06-29 Das Hasi R Novel diagnostic marker, a diagnostic kit and a method for diagnosis of rheumatoid arthritis
GB2426581A (en) 2005-05-27 2006-11-29 Univ Nottingham Immunoassay methods
EP1789435B1 (en) 2005-09-12 2010-02-24 Industry Foundation of Chonnam National University A method for production of mature natural killer cell
TWI304443B (en) 2005-12-30 2008-12-21 Nat Health Research Institutes Alpha-enolase specific antibody and method of use
CA2663154C (en) 2006-09-13 2016-02-23 Oncimmune Ltd Improved immunoassay methods
CN101632020B (zh) 2006-09-13 2013-11-27 昂西免疫有限公司 改进的免疫测定方法
GB0725239D0 (en) 2007-12-24 2008-02-06 Oncimmune Ltd Calibrator for autoantibody assay

Also Published As

Publication number Publication date
PT1889059E (pt) 2009-10-01
NO20161585A1 (no) 2008-02-26
US20140221245A1 (en) 2014-08-07
RU2636532C2 (ru) 2017-11-23
NZ563466A (en) 2009-12-24
SI1889059T1 (sl) 2009-12-31
IL215528A (en) 2015-10-29
US9719984B2 (en) 2017-08-01
IL215527A (en) 2013-04-30
IL187481A0 (en) 2008-02-09
RU2010149266A (ru) 2012-06-10
IL187481A (en) 2011-11-30
NO20161584A1 (no) 2008-02-26
CY1113013T1 (el) 2016-04-13
BRPI0610267B1 (pt) 2018-01-30
BRPI0610267A2 (pt) 2010-06-08
RU2010149267A (ru) 2012-06-10
CY1109461T1 (el) 2014-08-13
IL215527A0 (en) 2011-11-30
RU2662555C2 (ru) 2018-07-26
NO342101B1 (no) 2018-03-26
US9714938B2 (en) 2017-07-25
US20140234863A1 (en) 2014-08-21
IL215528A0 (en) 2011-11-30
NO341484B1 (no) 2017-11-27

Similar Documents

Publication Publication Date Title
NO20076656L (no) Forbedrede immunoassay metoder
MX2020009278A (es) Ensayos para detectar la neurodegeneración.
BRPI0707645B8 (pt) métodos in vitro para detecção de câncer em um indivíduo e para avaliação de prognóstico de um indivíduo tendo, ou suspeito de ter, câncer ovariano
BRPI0923199B8 (pt) método para determinar a presença de anticorpos de fixação de complemento
AR063125A1 (es) Ensayo elisa para la deteccion de vegf
WO2006026020A3 (en) Oncofetal fibronectin as a marker for disease and other conditions and methods for detection of oncofetal fibronectin
BR112015011040A2 (pt) calibração de testes usando tempo de reação
BRPI0915619A2 (pt) métodos para determinar uma probabilidade de que um sujeito tenha contribuído com material genético para amostra de teste de material genético, para caracterizar amostra de teste de material genético e para determinar se uma pessoa de interesse contribuiu com material genético para uma amostra de teste de material genético, kit para análise de amostra de teste de material genético e sistema para determinar se um sujeito contribuiu com material genético para uma amostra
WO2008021290A8 (en) Organ-specific proteins and methods of their use
NZ619883A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
DE60330248D1 (de) Teststreifen zum analytnachweis und verwendungsverfahren
ATE452343T1 (de) Verbesserte vitamin-d-messung
BR112016004320A2 (pt) biossensor, sistema, kit, métodos de determinação ou de identificação e de quantificação de uma concentração de amônia ou íon amônio, de diagnóstico de uma doença metabólica em um sujeito, de determinação da resposta do paciente a uma terapia, de fabricação de um biossensor, de um sistema ou de qualquer tira de teste e de detecção da presença, ausência, ou quantidade de aminoácidos em uma amostra, e, tira de teste
BR0317394A (pt) Uso de nicotinamida n-metiltransferase como um marcador para câncer colorretal
DK1513878T3 (da) Sammensætninger og fremgangsmåder til analyse af Apo B48 og Apo B100
ES2194116T3 (es) Procedimiento para detectar anticuerpos antipolimero y kit de prueba de diagnostico para uso como ayuda al diagnostico de las enfermedades relacionadas con silicona.
BR112014018204A8 (pt) Método de diagnóstico de distúrbio de células beta pancreáticas em um indivíduo
CL2022001084A1 (es) Sistemas y métodos de ensayo de flujo lateral para la cuantificación de una muestra biológica.
ATE508364T1 (de) Diagnoseverfahren für präeklampsie
PE20120592A1 (es) Metodo con biomarcadores para el seguimiento de un tratamiento
CY1109461T1 (el) Βελτιωμενες μεθοδοι ανοσολογικου προσδιορισμου
BR112013030646A2 (pt) uso diagnóstico de pró-somatostatina
BR9913770A (pt) Processo de ensaio para determinação da cobalamina ligada a transcobalamina ii (tcii) em uma amostra de corpo, kit para uso em um ensaio diagnóstico, e, uso de holo-tc ii
BRPI0519060A2 (pt) kit de teste rÁpido para a detecÇço e a localizaÇço de élceras nos eqÜinos e seu mÉtodo de produÇço
MX2022002328A (es) Metodos de un solo paso, kits, y sistemas para la medicion de concentraciones de bilirrubina no enlazada en fluidos biologicos.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/05/2006, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 17A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2724 DE 21-03-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.